Donepezil use for advanced Alzheimer's Disease - A case study from a long-term care facility

Journal of the American Medical Directors Association

Volumn 4, Issue 4, 2003, Pages 216-219

  Tariot, Pierre N ^a   Jakimovich, Laura ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Behavioral disturbances; Donepezil

Indexed keywords

ACETYLSALICYLIC ACID; ASCORBIC ACID; CALCIUM CARBONATE; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; DONEPEZIL; FERROUS SULFATE; GALANTAMINE; HALOPERIDOL; MULTIVITAMIN; PSYCHOTROPIC AGENT; RIVASTIGMINE; SERTRALINE; SORBITOL; THYROTROPIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; COGNITIVE DEFECT; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FUNCTIONAL DISEASE; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HUMAN; LABORATORY TEST; LONG TERM CARE; MALE; NURSING HOME; THYROTROPIN BLOOD LEVEL;

EID: 0041632203     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70349-7     Document Type: Article

References (14)

1. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-1371.
2. Green C, Marin D, Mohs R, et al. The impact of behavioral impairment of functional ability in Alzheimer's disease. Int J Geriatr Psychiatry 1999;14:307-316.
3. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
4. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
5. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000; 54:2261-2268.
6. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. Br Med J. 1999;318(7184):633-638.
7. Canadian Study of Health and Aging Working Group. Patterns of caring for people with dementia in Canada. Can J Aging 1994;13: 470-487.
8. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double, blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.
9. Morris J. The clinical dementia rating (CDR): Current version and scoring rules. Neurology 1993;43:2412-2414.
10. Tariot P, Cummings J, Katz I, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599.
11. Leon J, Cheng C-K, Neumann P. Alzheimer's disease care: Costs and potential savings. Health Aff 1998;17:206-216.
12. Kleinman L, Schmier J, Rothman M, et al. Time and costs of managing specific disruptive behaviors in long-term care facilities: A descriptive study. Consult Pharm 2002;17:497-507.
13. Tariot PN, Podgorski CA, Blazina L, Leibovici A. Mental disorders in the nursing home: Another perspective. Am J Psychiatry 1993;150:1063-1069.
14. Krauss N, Altman B. Research findings no. 5: Characteristics of nursing residents - 1996. Agency for Healthcare Research and Quality, Available at: http://www.meps.ahrq.gov/papers/rf5_99-0006/rf.htm. Accessed May 29, 2001.